explore -WSS

explore

author：comprehensive 2025-08-23 06:48:15 - browse：938

the Federal Trade Commission building and its brown sign — Adobe

A federal judge ordered Wednesday that Novant Health can move forward with its plan to buy two North Carolina hospitals, denying the Federal Trade Commission’s request for an injunction.

The FTC sued to block the deal in January, arguing that it would give Novant control of more than 65% of the region’s inpatient market. The case, one seeking to block nearby hospitals from merging and creating an even more powerful dominant player, is the FTC’s bread and butter. The agency has shied away from challenging cross-market and vertical mergers, but this one is right in its wheelhouse, which makes the setback surprising.

Under the deal, announced early last year, Novant would buy two hospitals in the same county from for-profit Community Health Systems for $320 million. The hospitals, Lake Norman Regional Medical Center and Davis Regional Medical Center, are only a 25-minute drive from one another. Davis Regional used to be a full-service hospital, but is now a psychiatric hospital. The deal also includes a group of 24 doctors, a majority interest in an endoscopy center, and a holding in a planned surgery center.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Merck to buy EyeBio, maker of eye drug, as it grows pipeline

WSS

Report: NIH

Nobel honors Karikó and Weissman's enduring partnership

Flu, Covid vaccination rates decline, new survey data show

The Karikó problem: Lessons for funding basic research

Startling documents reveal new facets of Sacklers' opioid empire

What we owe ALS patients — and why one company fell short

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Hollywood unions extend contract negotiations for actors

RSV injection headlines need to be accurate for good uptake

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

RSV injection headlines need to be accurate for good uptake

Alkermes shareholders re

Stigma and the return of syphilis

How to save PrEP access — and even expand it

The biotech scorecard for Q4: 16 stock

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What will Novo Nordisk's VC do with its influx of cash?

hotspot

Antibiotic resistance nearly killed me, so I'm raising awareness of it

IVG is promising — but it won’t replace IVF quite yet

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Flu, Covid vaccination rates decline, new survey data show

6 solutions to address cancer drug shortages and others

Experts study whether long Covid risk adds up with each reinfection

knowledge

focus

entertainment

knowledge